HLA-DP incompatibility is not considered as an exclusion criterion for bone marrow donors, because such incompatibility was not shown to affect significantly the risk for acute graft-versus-host disease (GVHD). In line with this clinical observation, it was proposed that in the context of bone marrow transplantation, HLA-DP determinants did not function as transplantation antigens in the same way as HLA-A, -B or -DR. In contrast to the above conclusion, we recently demonstrated the presence of HLA-DPB1*0501 specific T cell clones in a skin biopsy of a patient who developed aGVHD after receiving a bone marrow transplant (BMT) in which the only mismatched allele in the GVHD direction was HLA-DPB1*0501. At that time, this case was unique and occurred in a relatively uncommon graft setting where the patient received purified CD34 + BM cells from an unrelated donor. In the present study, we analyzed the immunological events associated with an aGVHD which occurred in the context of a 'regular' allogeneic BMT involving a single HLA-DPB1*1001 mismatch between donor and recipient in the GVHD direction. To this end, we analyzed several amplified T cell subsets present within a T cell line derived from a skin biopsy performed at the onset of GVHD. Our results demonstrated that T cell populations belonging to the TCRBV2, TCRB6.7, TCRBV14 and TCRBV17 subsets were specific for the HLA-DPB1*1001 mismatched allele. These data strengthen and generalize our first conclusion that a single HLA-DP mismatch between donor and recipient can activate a strong T cell response in vivo and consequently challenge the notion that HLA-DP incompatibility should not be taken into account in the choice of BM donors. Moreover, they also underline the idea that HLA-DP antigens may represent an interesting immune target for future therapeutic approaches. Keywords: transplantation; HLA-DP; GVH Allogeneic bone marrow transplantation (BMT) can be successfully used to treat patients with several hematologic malignancies or severe aplastic anaemia. The major complication of this procedure is graft-versus-host disease (GVHD) with a risk of 20-50% when donor and recipient are HLA-identical siblings.
Keywords: transplantation; HLA-DP; GVH Allogeneic bone marrow transplantation (BMT) can be successfully used to treat patients with several hematologic malignancies or severe aplastic anaemia. The major complication of this procedure is graft-versus-host disease (GVHD) with a risk of 20-50% when donor and recipient are HLA-identical siblings. 1 When no HLA-identical sibling is available (which is the case for more than 60% of patients), matched or partially mismatched unrelated donors represent an alternative source of bone marrow. 2, 3 Unfortunately, the rate of GVHD and rejection appears to increase with the extent of HLA mismatch. With respect to HLA disparities, the increased risk of aGVHD associated with HLA-A, -B, -DR mismatches between donor and recipient is well established. 2 In contrast, concerning HLA-DP incompatibility, conclusions drawn from clinical statistics or biological data are apparently conflicting: although severe GVHD following HLA-DP incompatible, but otherwise HLA-identical, BMT has been reported by several groups, recent analysis of a large series of patients did not confirm that HLA-DP antigens played a significant role in the incidence of severe acute GVHD (see Refs 4 and 5 for review). From these clinical observations, it was deduced that contribution of genomic differences in the DP region to alloreactivity and GVHD could be questioned. These conclusions were difficult to reconcile with our own data concerning the specificity of T cells invading the skin at the onset of GVHD. Indeed, we have demonstrated the presence of HLA-DP-specific T cells in the skin of patients who developed GVHD after semi-allogeneic BMT, each time an HLA-DP mismatch was present. [6] [7] [8] However, only once did we have the opportunity to analyze a graft setting where HLA-DP was the only documented mismatch in the GVHD direction. In that case, we could demonstrate that a large fraction of skin-infiltrating T lymphocytes expressing diverse T cell receptors were reactive against HLA-DPB1*0501, the only mismatch of the graft. 8 This observation, which challenged the notion that the HLA-DP determinant does not function as a transplantation antigen in the same way as HLA-A, -B or -DR, not only was unique, but was also performed in the context of a relatively uncommon graft setting since the patient received an allogeneic BMT of CD34 + BM-purified precursors. Because it was recommended that HLA-DP incompatibility should not be considered as an exclusion criterion for BM donors, we thought that a generalization of our previous observation concerning the biological importance of a single HLA-DP mismatch might have important clinical implications. The present study was initiated to confirm and generalize our previous results. To this end, we took advantage of another acute GVHD which occurred after an allogeneic unrelated BMT, and where HLA-DPB1*1001 was the single mismatched allele of the graft in the GVHD direction. The experimental protocol was designed to solve rapidly the two main questions: (1) could a single HLA-DP mismatched allele trigger in vivo a specific T cell response in this graft situation; and (2) if so, is it mediated by T cells expressing restricted T cell receptors. Our results demonstrated that in this 'regular' graft setting, acute GVHD was associated with the presence in the skin of activated T cells expressing diverse TCRBV regions and specific for HLA-DPB1*1001, the only mismatched HLAallele of the graft.
Patient and methods

Case report
The patient, a 42-year-old male was allografted on 31 March 1992 from an unrelated female donor. Patient and donor were CMV-negative and serologically matched for HLA-A and -B and matched at HLA-DRB1 and -DQB1 locus. They were mismatched for HLA-DPB1 with an HLA-DPB1*1001 mismatched allele in the GVH direction. The reason for transplantation was Richter's syndrome in first partial response after two lines of anthracyclin-containing polychemotherapy. The conditioning regimen consisted of fractionated 12 Gy total body irradiation with lung shielding at 8 Gy followed by cyclophosphamide 60 mg/kg on each of 2 consecutive days. Unmanipulated noncryopreserved donor's marrow was injected on day 0. The prophylaxis of graft-versus-host disease consisted of cyclosporin A at a dose of 3 mg/kg/day as a continuous i.v. infusion from day 1, together with methotrexate 15 mg/m 2 day 1 and 10 mg/m 2 day 3 and 6. The patient was in a laminar air flow room from the end of total body irradiation until death. Engraftment was documented on day 18. Grade III acute graft-versus-host disease started on day 16. Heavy immunosuppressive therapy combining steroids, cyclosporine, anti-RIL2 (BB10, Biotest, Buc, France) and anti-TNF monoclonal antibodies allowed improvement in graft-versus-host disease. However, on day 66, invasive aspergillosis occurred unresponsive to available antifungal agents leading to the death of the patient on day 75. At time of death, the marrow aspirate was consistent with a complete response of the hematologic disease.
Obtaining skin infiltrating T cells and TCRBV subsets
The skin specimen (a 4-mm punch biopsy) was washed five times in medium containing 10% pooled human sera, 1% l-glutamine (2 mm), 50 g/ml gentamycin and was cultured in a 24-well plate (Nunclon, Copenhagen, Denmark) in the same medium supplemented with recombinant interleukin 2 (rIL-2, 150 BRMP U/ml). Cultures were kept at 37°C in a 5% CO 2 atmosphere. Once T cells grew out of the biopsy, 3 days after initiation of the culture, they were stimulated using a polyclonal activation procedure: biopsy infiltrating T cells were seeded in 75 cm 2 culture flasks in 20 ml of culture medium together with pooled allogeneic feeder cells (5 × 10 6 PBL and 5 × 10 5 B lymphoblastoid cell line (BLCL), 30 Gy irradiated) in the presence of 1 g/ml leukoagglutinin-A (Pharmacia, Uppsala, Sweden), and rIL-2 (150 BRMP U/ml). These conditions, where virtually 100% of T cells are stimulated, 9 were chosen to avoid in vitro antigenic selection, while maintaining as nearly as possible the best representation of T cells which grew under rIL-2 alone during the initial culture period, ie the in vivo activated T cells infiltrating the biopsy. The T cell line was aliquoted and cryopreserved in liquid nitrogen. After thawing, to generate a panel of T cell clones one responder T cell was seeded in every three culture wells in 96-microwell round bottom culture plate together with pooled allogeneic feeder cells: (5 × 10 4 PBL and 5 × 10 3 B lymphoblastoid cell line (BLCL) per well, 30 Gy irradiated) in the presence of 1 g/ml leukoagglutinin-A (Pharmacia), and rIL-2 (150 BRMP U/ml). Clones were derived from the bulk culture after the first restimulation. For repertoire analysis, screening with the panel of TCRBV-specific mAb was performed on the bulk culture after the first restimulation and immunoscope analysis was performed on RNA purified from the bulk culture after the second restimulation.
Proliferation assay
Resting T cells (2.5 to 5 × 10 4 ), taken more than 2 weeks after the last stimulation, were cocultured for 48 to 72 h 
Flow cytometry
The following TCRBV region-specific mAbs (from Immunotech, Marseilles, France) were used for flow cytometry:
) and HUT78Ͻ1 (anti-BV23S1) (references compiled in the 1995 TCR Workshop, San Francisco). Cells were stained by two color immunofluorescence using phycoerythrin (PE)-conjugated anti-CD3 from Immunotech and unconjugated TCRBV region-specific mAb, whose binding was revealed by RAM-FITC-conjugated goat antimouse IgG antiserum (from Bioatlantic, Nantes, France). A three-step procedure was used for staining: T cells were incubated 30 min on ice in V-bottomed microtiter plates in the presence of 25 l of the first mAb at the optimal concentration. Cells were further incubated in the presence of RAM-FITC for 30 min. After washing, cells were incubated for 30 min on ice with (PE)-conjugated anti-CD3 mAb. An anti-rat kappa chain was used as a negative control. Between each step, plates were centrifuged and supernatant discarded by flicking. Wells were washed twice with 200 l ice-cold 0.1% phosphate-buffered saline bovine serum albumin (PBS-BSA). Labelled cells (5000) were analyzed using a Facscan flow cytometer (Becton Dickinson, Mountain View, CA, USA).
Cytotoxic assay
Cytotoxic activity was tested using a standard chromium release assay: briefly, target cells were labelled with 100 Ci Na 2 51 CrO 4 for 1 h at 37°C, washed four times and then plated at a 50:1 effector-to-target ratio in a 96-well round-bottom culture plate. After 4 h of incubation at 37°C, 25 l of supernatant from each well was removed and counted in a gamma scintillation counter. Each test was performed in triplicate. Results are expressed as percentage of lysis, according to the following formula: (experimental release − spontaneous release)/(maximal release − spontaneous release) × 100, where experimental release Table 1 HLA-typing of host donor and BLCL used for the study Host and donor cells were not available at the time of study. Consequently, specificity determination were performed using the following B lymphoblastoid cell lines (BLCL): MK and C3, which were derived from genotyped blood bank donors by coculturing PBL with EBV containing supernatant from the virus-producing B95.8 cell line in the presence of 1 g/ml CsA, and BTB and HOM2 which are from the 1987 HLA-Workshop in New York.
represents mean counts per minute released from the target cells in the presence of effector cells, spontaneous release that from target incubated without effector, and maximum release that from target incubated with 1% cetavlon. For blocking experiments target cells were incubated for 30 min at room temperature in the presence of the indicated mAb at optimal dilution previously tested (ie 1/100, 2 g/ml).
Immunoscope analysis
TCR ␤ chain-specific primer were as in Ref. 10 , except for BV6 (5′ CTC TGA AGA TCC AGC GCA CAC AGC) and BV21 (5′ TCC AGC CTG CAA AGC TTG AGG ACT). RNA was extracted as previously described. 11 Fluorescent DNA products were migrated on sequencing gels in an automated DNA sequencer (Applied Biosystems, Foster City, CA, USA), and raw data were analyzed by the immunoscope software package.
11,12
Results
Method used to obtain biopsy-infiltrating T cells (BIL)
Sixteen days after transplantation, a skin rash was observed and GVHD was suspected. A 4-mm skin punch biopsy was performed and processed as described in the Patient and methods section. T cells recovered after culturing the skin biopsy in the presence of IL-2 alone were then restimulated under conditions that trigger the growth of virtually all T cells present in the culture. This procedure was designed to select most in vivo activated T cells during the first culture step and to recover after the second step all T cells selected during the first one. [6] [7] [8] As indicated in the Patient and methods section, repertoire analysis with mAbs was performed on the bulk culture after the first restimulation and immunoscope analysis after the second. The BIL cell line was CD4 + , CD8 − , CD16 − , TCR␥␦ − , TCR␣␤ + (data not shown).
Analysis of T cell repertoire diversity of skin infiltrating T cells
To produce their antigenic receptor, ␣␤ T lymphocytes use combinations of different TCR-V, -D and -J elements (VDJ for ␤ chain and VJ for ␣ chain). Beside this combinatorial diversity, addition and/or removal of nucleotides at the junction of the rearranged genes generate a junctional diversity. Combinatorial (TCR-V gene usage), as well as junctional diversity, are now both amenable to analysis. TCRBV expression within BIL T cells was first studied by two-color flow cytometry using anti-CD3 mAb (red fluorescence) and mAbs specific for a large set of TCRBV regions (green fluorescence) covering close to 60% of the total T cell repertoire.
9 Figure 1 shows the composition of the T cell repertoire detected among BIL T cells. As one can see, most subsets were barely detectable except five, each representing more that 5% of the whole CD3 + population: TCRBV17, TCRBV14, TCRBV9, TCRBV6.7 and TCRBV2. Whether these TCRBV subsets were diverse or not could not be deduced from the above analysis using mAbs. Consequently, the BIL T cell repertoire was further investigated by analyzing the distribution of TCR CDR3 length with a recently described technique termed immunoscope. [10] [11] [12] This technique, which involves a combination of PCR and run-off reactions using pairs of V␤/C␤ primers followed by size determination of the elongation's products allow determination of TCR CDR3 length distribution within each of the TCRBV subsets studied. Among normally diverse T cell populations, a Gaussian-like distribution of CDR3 length is observed. 10 In contrast, monoclonality or oligoclonality leads to the detection of a single or several isolated peaks on the immunoscope profile.
Such an analysis of BIL T cells is shown on Figure 2 . Some TCRBV subsets were virtually absent (TCRBV1, TCRBV11, TCRBV16 and TCRBV24) or barely detectable above background (TCBV15, TCRBV22 and TCRBV23) and for the others, only one to three dominant peaks were detected, suggesting the presence of a single or a few clones within each of the TCRBV subsets. Note that the TCRBV9 population, which represented half of the CD3
+ T cells present in the bulk culture was not more diverse than the TCRBV20 subset which represented less that 5% of the CD3 + .
Specificity of clones derived from the biopsy-infiltrating T cells
The above analysis of BIL T cells diversity, as well as previously published results, 8, 13, 14 strongly suggested that dominant peaks detected here within TCRBV subsets reflected the presence of a single dominant clone. Consequently, to rapidly answer the question as to whether a diverse T cell response was directed against the mismatch HLA allele of the graft, T cell clones were derived from BIL cells by limiting dilution culture and screened with the panel of TCRBV-specific mAb. Thereafter, a single clone from each TCRBV family was kept for further studies. Six different clones were obtained, which belonged to the best represented TCRBV subsets, ie TCRBV2, BV6.7, BV9, BV14 and BV17. All were CD4 + CD8 − (data not shown). Clone specificities were determined in a classical manner using HLA-framework specific mAb and a panel of genotyped BLCL. HLA-typing of host, donor and BLCL used for specificity testing are indicated in Table 1 . An example of determination is shown in Figure 3 . T cell clones TCRBV2, -BV6.7, -BV14, and -BV17 did not proliferate against HOM2 and BTB but showed a strong proliferative response against BRA, MK and C3. Moreover, proliferation of each clone against a stimulating BLCL was blocked by an anti-HLA-DP-specific mAb but remained unaffected by the addition of mAb against HLA-DQ or -DR. Consequently, these clones were specific for HLA-DPB1*1001, the mismatch allele of the graft in the GVHD direction. No reactivity against any of the BLCL tested could be detected for the clone belonging to the TCRBV9 subset. Because our screening procedure uses BLCL as targets to present the mismatch allele of the graft we cannot exclude that the CD4 + clone TCRBV9 was specific for a tissue specific or a minor histocompatible antigenic difference between donor and recipient, since it has been shown that BLCL might not present adequately MHC class II restricted minor antigens.
15 Figure 4 shows that clones TCRBV2, TCRBV6.7 and TCRBV14 were able to directly kill an HLA-DPB1*1001-bearing BLCL, whose killing was blocked by the HLA-DP-specific mAb, but not by mAb directed at HLA-DQ or -DR.
Discussion
We have recently demonstrated the presence of HLA-DPspecific T cells in the skin lesions of patients who developed GVHD after semi-allogeneic or allogeneic BMT. [6] [7] [8] Only in one circumstance did we have the opportunity to document the presence of HLA-DP-specific T cells within the skin at the onset of GVHD when the HLA-DP-mismatched allele represented the single HLA mismatch of the graft. 8 Because of its potential clinical implications, the present study was initiated to confirm and generalize our former conclusion that a single HLA-DP mismatch can drive a strong T cell response in vivo. To this end, we studied a case of GVHD which occurred in a patient who received an allo-BMT with a single HLA-DPB1*1001 mismatch (extensive HLA-typing of host and donor could identify only one potential HLA-class I mismatch allele, HLA-B702 or 705). Analysis of skin-infiltrating T cell clones revealed that 4/5 belonging to TCRBV subsets, which represented altogether close to 30% of the biopsy-derived T cell line, were specific for HLA-DPB1* 1001.
Although we detected only HLA-DPB1*1001-specific T cells, it remained difficult to ascertain whether they were the only ones to participate in the GVHD process. That alloreactivity against MHC molecules is not the only factor influencing GVHD is clear from its occurrence between HLA-identical siblings (20-50%). 1 In this context, minor histocompatibility antigen disparity has been shown to increase the risk of GVHD 16 and such disparity is bound to be even greater between unrelated, than between genoidentical individuals. 17 Moreover, in the present case, donor and recipient are not only unrelated but also sex-mismatched (female to male). Consequently, we cannot exclude that among T cells present in the skin which were not specific for HLA-DPB1*1001, some were specific for minor antigenic differences between donor and recipient. In particular this might be the case for the TCRBV9 subset, which represented half of the T cells obtained from the biopsy and which did not recognize any of the BLCL we used for stimulation. Nevertheless, our data conclusively demonstrated the occurrence of an in vivo alloreaction against the HLA-DPB1*1001-mismatched allele.
Demonstration that a single HLA-DP mismatch can drive a strong immunological response in vivo has important clinical implications. First, because HLA-DP incompatibility was not shown to detectably influence the risk of GVHD, it was logically recommended that HLA-DP incompatibility should not be taken as an exclusion criterion for BM donors. 4 As far as the choice remains possible, and being aware that GVHD is also linked to many other risk factors (such as sex-mismatch, donor age, immunosuppressive therapy, T cell depletion, minor antigenic differences), the notion that HLA-DP incompatibility should not be taken in account might be questioned in the light of our results. On the other hand, because HLA-DP can trigger a strong in vivo response, one can consider taking advantage of HLA-DP as a potential target for immunotherapy post-BMT. Indeed, it is now well established that post-BMT alloreactivity is not necessarily only harmful, but it can also have a beneficial effect, ie it can promote a graftversus-leukemia reaction (GVL). [18] [19] [20] [21] Because the GVL effect is most evident for hematologic malignancies, an immune target for a GVL effect should be restricted to the hematopoietic lineage, which is usually the case for HLAclass II antigens. Moreover, in line with such a strategy, the five most frequent HLA-DPB1 alleles (HLA-DPB1* 0101, 201, 301, 401, 402) cover more than 80% of the Caucasian population. Taken together, these considerations led us to propose recently the use of HLA-DP-specific T cell clones, transfected with a suicide gene, to induce and control a GVH-GVL reaction as an adjuvant therapy in the case of HLA-class II bearing hematologic malignancies. 8, 19 The data presented in this paper further validate the immunological pertinence of such a strategy.
